Participant retention in clinical trials of candidate HIV vaccines

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 4, 2005, Pages 499-501

  De Bruyn, Guy ^a,b   Hudgens, Michael G ^c,d   Sullivan, Patrick S ^a,e   Duerr, Ann C ^a  

^a HIV Vaccine Trials Network   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Fred Hutchinson Cancer Research Center   (United States)

^d IL   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Aids vaccines; Human; Loss to follow up; Randomized controlled trials; Regression analyses

Indexed keywords

ALUMINUM POTASSIUM SULFATE; DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL MODEL;

ADULT; AGE FACTORS; AIDS VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; MALE; ODDS RATIO; PATIENT DROPOUTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 22344455046     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000148532.12329.df     Document Type: Article

References (10)

1. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet. 2002;359:781-785.
2. Scheer S, Douglas JM, Jr, Vittinghoff E, et al. Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 1999;20:172-178.
3. Screening, recruiting and predicting retention of participants in a multisite HIV prevention trial. NIMH Multisite HIV Prevention Trial. AIDS. 1997; 11(Suppl 2):13-19.
4. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:619-627.
5. Marmor M, Titus S, Wolfe H, et al. Preparations for AIDS vaccine trials. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. AIDS Res Hum Retroviruses. 1994;10(Suppl 2):207-213.
6. Graham BS. Clinical trials of HIV vaccines. Annu Rev Med. 2002;53: 207-221.
7. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982;97:362-366.
8. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833-841.
9. Gilliss CL, Lee KA, Gutierrez Y, et al. Recruitment and retention of healthy minority women into community-based longitudinal research. J Womens Health Gend Based Med. 2001;10:77-85.
10. Neter J, Kutner M, Nachtsheim C, et al. Applied Linear Statistical Models. 4th ed. Columbus: McGraw Hill-Irwin; 1996.